

CHAIR-SIDE REFERENCE: AGE-RELATED MACULAR DEGENERATION


AGE-RELATED MACULAR DEGENERATION (AMD)

- This chair-side reference was designed to assist practising optometrists in distinguishing between the different stages and phenotypes of AMD. Current clinical guidelines stipulate that essential components of the clinical examination for the diagnosis of AMD includes a targeted case history, high-contrast visual acuity, refraction, stereoscopic slit lamp examination of the macula, dilated fundus examination of. It is also recommended to supplement clinical examination with available ocular imaging. Please note, this document provides general information only and may not be applicable to atypical cases.
- For further information, readers are encouraged to review the full texts:
 - Ferris et al. Clinical Classification of Age-related Macular Degeneration. Ophthalmology 2013;120:844-851
 - Sadda et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3. Ophthalmology 2018;125:537-548
 - Agrón E, et al. for the AREDS and AREDS2 Research Groups, An Updated Simplified Severity Scale for Age-Related Macular Degeneration, Incorporating Reticular Pseudodrusen: Age-Related Eye Disease Study Report No. 42, Ophthalmology (2024)

GRADING AMD Retinal Photo Fundus autofluorescence Optical coherence tomography Description **Normal Aging Changes** Drupelets only (<63µm diameter, up to approximately half the width of a major branch retinal vein crossing the optic disc margin) Should not show any pigmentary abnormalities or other characteristics of early, intermediate or late AMD FAF may appear near normal or display punctate spots of hyper- or hypoautofluorescence OCT shows discrete irregularities or elevations of the RPE or may be too small to resolve Early AMD Medium drusen only (63 to 125µm diameter) Should not show any pigmentary abnormalities or other characteristics of intermediate or late AMD FAF appearance is similar to drupelets, medium drusen may display a variable normal, hyper- or hypofluorescence pattern Drusen typically appear as nodular elevations of the RPE/Bruch's membrane complex with medium internal reflectivity on OCT Intermediate AMD Large drusen (>125µm in diameter) and/or hyper/hypopigmentary abnormalities associated with at least medium drusen No characteristics of late AMD May feature a range of FAF patterns, depending on the nature of the drusenoid deposits, including: normal, minimal change, focal increased, patchy, linear, lacelike, reticular, speckled, focal confluent, focal plague-like or scattered OCT shows dome shaped, occasionally confluent, elevations of the RPE, with visible underlying BM. Hyperpigmentary abnormalities may appear as discrete hyper-reflective foci with posterior shadowing



CHAIR-SIDE REFERENCE: AGE-RELATED MACULAR DEGENERATION



This reference is based on the current literature and evidence at the time of writing. This reference is designed a guide to aid diagnosis and management decisions however individual cases must be assessed in the context of all available clinical data.

Abbreviations: AMD, Age-related macular degeneration; OCT, Optical coherence tomography; FAF, Fundus autofluorescence; RPE, Retinal pigment epithelium; BM, Bruch's membrane; ISe, Inner segment ellipsoid; ELM, External limiting membrane;

ONL, Outer nuclear layer; HFL, Henle's fibre layer; GA, Geographic atrophy; FA, Fluorescein angiography; PED, Pigment epithelium detachment



One-to-one consultation with a senior CFEH optometrist for non-urgent diagnosis and management support. Interactive, therapeutic CPD points.

Consultations are complimentary, thanks to the generous support of Guide Dogs NSW/ACT.



CHAIR-SIDE REFERENCE: AGE-RELATED MACULAR DEGENERATION


DISEASE PROGRESSION IN INTERMEDIATE AMD

The advent of OCT imaging allows clinicians to identify structural risk factors that may predict progression in intermediate AMD. These biomarkers may help in risk stratification and subsequently allow clinicians to offer tailored and individualized management plans. Below is an evidence-based summary of prognostic biomarkers that may predict a higher risk of progression from intermediate to late AMD, organised according to the strength of available evidence. Importantly, this field of research is highly active and rapidly evolving, particularly with the growing integration of artificial intelligence and machine learning.

PROGNOSTIC BIOMARKERS WITH HIGH STRENGTH OF EVIDENCE

High Drusen Volume






RPE Elevations	Current
Area in 3 mm Circle (mm²)	0.7
Area in 5 mm Circle (mm²)	0.7
Volume in 3 mm Circle (mm³)	0.04
Volume in 5 mm Circle (mm³)	0.04
Sub-RPE Illumination	Current
Area in 5 mm Circle (mm²)	0.0
Closest distance to Fovea (mm)	XXX

High drusen volume at the macula is the strongest risk factor for AMD progression. Drusen volume can be established qualitatively (a higher number of visible drusen at the macula confers a higher risk of progression), or quantitatively using some commercially available OCT software.

A drusen volume greater than or equal to 0.03mm³ within a 3mm central circle is associated with a four-fold increase in progression risk from intermediate to late AMD when compared with drusen volume less than 0.03mm³ (Abdelfattah et al. 2016).

Images show a retinal photograph and Cirrus Advanced RPE Analysis of a patient with high drusen volume.

Reticular Pseudodrusen



Updated AREDS Simplified Severity Scale (2024)

Score	AREDS SSS (no RPD)	AREDS SSS (with RPD)
0	~0.5%	3%
1	~4%	8%
2	12%	~30%
3	~25%	~60%
4	50%	~70%

Reticular pseudodrusen (RPD) are deposits in the sub-retinal space (above the RPE) and are distinct from conventional drusen which are located underneath the RPE. On FAF imaging, they present with an interlacing or reticular pattern. They can be associated with progression to both forms of late AMD.

While there is still debate on the validity and utility of biomarkers and scales, the previously widely used AREDs Simplified Severity Scale was updated in 2024 to reflect the presence or absence of reticular pseudodrusen (table 1).

The AREDS Simplified Severity Scale estimates the risk of progression to late AMD within 5 years by assessing both eyes. The scoring system is as below:

- One point for each eye that has large drusen present
- One point for each eye that has pigmentary abnormalities at the macula
- If neither eye has large drusen, one point is still assigned if both eyes have medium-sized drusen.


POTENTIAL BIOMARKES THAT MAY INDICATE PROGRESSION OF INTERMEDIATE AMD

Hyper-reflective Foci


Nascent Geographic Atrophy

Hypo-reflective Drusen Cores


Altered Integrity of Outer Retinal Hyper-reflective Bands




Discrete, well circumscribed, punctate lesion often overlying drusen



A hyporeflective, wedge-shaped band within the limits of the OPL and/or subsidence of the OPL and INL



Hypo-reflective or darker areas within drusen cores seen on OCT



Interruptions in hyperreflectivity, irregularity or attenuation of the ELM, EZ or IZ